Brokerages Anticipate Syndax Pharmaceuticals Inc (SNDX) Will Post Earnings of -$0.76 Per Share

Share on StockTwits

Wall Street brokerages expect Syndax Pharmaceuticals Inc (NASDAQ:SNDX) to post earnings of ($0.76) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Syndax Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.94) and the highest estimate coming in at ($0.57). Syndax Pharmaceuticals posted earnings per share of ($0.68) during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.8%. The company is expected to announce its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Syndax Pharmaceuticals will report full year earnings of ($3.12) per share for the current fiscal year, with EPS estimates ranging from ($3.52) to ($2.74). For the next financial year, analysts expect that the business will post earnings of ($3.19) per share, with EPS estimates ranging from ($4.63) to ($2.07). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Syndax Pharmaceuticals.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 7th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.13. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 3,190.51% and a negative return on equity of 80.35%.

SNDX has been the subject of several analyst reports. ValuEngine upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Finally, HC Wainwright initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $30.00 target price for the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.00.

A number of institutional investors and hedge funds have recently bought and sold shares of SNDX. Macquarie Group Ltd. bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at $1,264,000. Bank of America Corp DE boosted its stake in shares of Syndax Pharmaceuticals by 1,382.0% in the 2nd quarter. Bank of America Corp DE now owns 28,084 shares of the company’s stock valued at $197,000 after purchasing an additional 26,189 shares during the last quarter. DRW Securities LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at $105,000. Stonepine Capital Management LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at $1,393,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Syndax Pharmaceuticals by 40.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 558,725 shares of the company’s stock valued at $3,922,000 after purchasing an additional 161,146 shares during the last quarter. 75.08% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:SNDX traded up $0.27 during midday trading on Tuesday, hitting $7.25. The stock had a trading volume of 13,607 shares, compared to its average volume of 284,985. The stock has a market capitalization of $167.69 million, a PE ratio of -2.49 and a beta of 1.09. Syndax Pharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $15.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Featured Article: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply